Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Hwang (Iksan, Republic of Korea), S. Oh (Iksan, Republic of Korea), E. Jeong (Iksan, Republic of Korea), H. Kim (Iksan, Republic of Korea). Inhibitory effects of mitochondrial TRAP1 on gefitinib-resistancein non-small lung cancer cells. 5379

Member's Comments

No comment yet.

Related content which might interest you: Deguelin enhances chemosensitivity of non-small cell lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006 Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 Expression of RASGRF2 in non-small cell lung cancer and its effect of transfection on biological behavior of human NSCLC lines H1299 Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012 Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011 Expression of ERCC1 in normal and tumor tissues in non-small cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005 Influence of overexpression of coagulantic and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Update on nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 173-185 Year: 2010 Expression of p53, Bcl-2 and Bax in non-small cell lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 512s Year: 2007 Choice of endogenous control for gene expression in nonsmall cell lung cancer Source: Eur Respir J 2005; 26: 1002-1008 Year: 2005 IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer Source: Eur Respir J , 49 (4)  1600711; DOI: 10.1183/13993003.00711-2016 Year: 2017 Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008